Serum Prolidase Enzyme Activity Level: Not a Predictive Biomarker for Epilepsy

Area of Science:

• Biochemistry
• Neurology
• Clinical Medicine

Background:

• Epilepsy pathogenesis is linked to oxidative stress (OS) and inflammation.
• Prolidase enzyme activity (PEA) plays a role in proline metabolism, collagen synthesis, and is associated with OS and inflammation.
• No prior studies have investigated the relationship between epilepsy and PEA.

Purpose of the Study:

• To assess postictal serum prolidase enzyme activity (PEA) levels in epilepsy patients.
• To determine if PEA can serve as a potential biomarker for epilepsy, given its association with OS and inflammation.

Main Methods:

• The study included 27 epilepsy patients presenting within 6 hours of a seizure and 31 healthy controls.
• Serum PEA levels were measured in both the epileptic and control groups.

Main Results:

• The mean age of the epilepsy group was 43.1±20.2 years, and the control group was 51.9±21 years.
• Serum PEA levels were 1171.90±343.3 in the epileptic group and 1137.1±295.6 in the control group.
• No statistically significant difference in PEA levels was observed between the epilepsy and control groups (p>0.05).

Conclusions:

• Despite its known association with OS and inflammation, prolidase enzyme activity (PEA) is not an ideal biomarker for epilepsy.
• This research is the first to investigate PEA in patients with idiopathic epilepsy.